Literature DB >> 33773462

The emerging role of KIAA1199 in cancer development and therapy.

Jingmei Liu1, Wei Yan1, Ping Han2, Dean Tian3.   

Abstract

KIAA1199, also known as CEMIP or HYBID, is an important member of the Human Unidentified Gene-Encoded (HUGE) database. Accumulated evidence has revealed that KIAA1199 is associated with tumor progression and metastasis in numerous malignancies, including colorectal, liver, gastric, pancreatic, breast, lung, prostate, ovarian and papillary thyroid cancers. As an oncogene, it plays crucial role in the proliferation, apoptosis, invasion and migration of various tumor cells. In addition, KIAA1199 is also involved in the regulation of multiple signal pathways such as epithelial-mesenchymal transition (EMT), Wnt/ β-catenin, MEK/ERK and PI3K/Akt. In this review, we summarized up to date advancement on the role of KIAA1199 in human cancer development, progression, and metastasis. We also addressed KIAA1199 as a potential therapeutic target for cancer therapy.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Cancer; EMT; KIAA1199; Therapy; Wnt/ β-catenin

Year:  2021        PMID: 33773462     DOI: 10.1016/j.biopha.2021.111507

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  High Expression of CEMIP Correlates Poor Prognosis and the Tumur Microenvironment in Breast Cancer as a Promisingly Prognostic Biomarker.

Authors:  Xingxing Dong; Yalong Yang; Qianqian Yuan; Jinxuan Hou; Gaosong Wu
Journal:  Front Genet       Date:  2021-12-13       Impact factor: 4.599

Review 2.  Hyaluronan Functions in Wound Repair That Are Captured to Fuel Breast Cancer Progression.

Authors:  Cornelia Tolg; Britney Jodi-Ann Messam; James Benjamin McCarthy; Andrew Cook Nelson; Eva Ann Turley
Journal:  Biomolecules       Date:  2021-10-20

3.  CEMIP Promotes Osteosarcoma Progression and Metastasis Through Activating Notch Signaling Pathway.

Authors:  Jun Cheng; Yan Zhang; Rongjun Wan; Jun Zhou; Xin Wu; Qizhi Fan; Jingpeng He; Wei Tan; Youwen Deng
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.